Literature DB >> 1938561

Radiotherapy in the management of cutaneous epidemic Kaposi's sarcoma.

F Geara1, J P Le Bourgeois, P Piedbois, J M Pavlovitch, J J Mazeron.   

Abstract

Between June 1986 and December 1988, we treated 149 patients who had AIDS-related epidemic Kaposi's sarcoma with cutaneous irradiation. According to Mitsayasu's staging, 34 patients (23%) had Stage I disease, 82 (55%) Stage II, 0 Stage III, and 33 (22%) Stage IV. Fifty-eight patients (39%) had previously presented with one or more opportunistic infections. Ninety-four patients (63%) had received previous treatment of their Kaposi's sarcoma: 85 (57%) with interferon and 43 (29%) with vinblastine. Among the 149 patients, we treated 88 (59%) with extended cutaneous irradiation using 4- and/or 8-MeV electron beam energy and 61 patients (41%) with localized irradiation using 45-kVp x-ray energy. The total prescribed dose was 30 Gy: 20 Gy in 2 weeks (2.5 Gy/fraction, 4 times/week), followed by 2 weeks of no irradiation, and then 10 Gy in one week by the same dose schedule. Twenty patients (13%) with edema of the lower limbs were treated using 4-Mv photon therapy with bolus. Of the 131 evaluable patients, 63% achieved a complete remission (CR) and 30% a partial remission (PR) after a mean period of 1.5 months (range: 0.5-3 months). The clinical disease stage, anatomic site, and irradiation technique did not significantly influence the remission rates, although we noticed a higher CR rate when localized irradiation was used (71% vs 55.5% for localized and extended irradiation, respectively; p = 0.08). The overall tolerance was acceptable. Complications were severe epidermitis with skin ulcerations (8% of patients), exudative epidermitis (26%), dry epidermitis (60%), and varying degrees of erythema (6%). Of the 87 patients whose AIDS remained relatively clinically stable during the observation period, recurrences occurred in 56 (64%) after an average of 5.5 months (range: 1.5-12 months). We conclude that radiotherapy is useful and can be recommended as a palliative treatment to relieve pain and physical discomfort or to achieve cosmetic improvements for patients with epidemic Kaposi's sarcoma. We also conclude that radiotherapy is most beneficial in the early stages of disease, when localized treatment is practical.

Entities:  

Mesh:

Year:  1991        PMID: 1938561     DOI: 10.1016/0360-3016(91)90327-z

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  4 in total

1.  Antiproliferative effect of retinoid compounds on Kaposi's sarcoma cells.

Authors:  J Corbeil; E Rapaport; D D Richman; D J Looney
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

2.  Critical appraisal of volumetric-modulated arc therapy compared with electrons for the radiotherapy of cutaneous Kaposi's sarcoma of lower extremities with bone sparing.

Authors:  G Nicolini; S Abraham; A Fogliata; A Jordaan; A Clivio; E Vanetti; L Cozzi
Journal:  Br J Radiol       Date:  2013-02-07       Impact factor: 3.039

3.  Evaluation of treatment plans using various treatment techniques for the radiotherapy of cutaneous Kaposi's sarcoma developed on the skin of feet.

Authors:  Jong Min Park; Il Han Kim; Sung-Joon Ye; Kyubo Kim
Journal:  J Appl Clin Med Phys       Date:  2014-11-08       Impact factor: 2.102

4.  A Series of Patients with Kaposi Sarcoma (Mediterranean/Classical Type): Case Presentations and Short Update on Pathogenesis and Treatment.

Authors:  Ivanka Temelkova; Michael Tronnier; Ivan Terziev; Uwe Wollina; Ilia Lozev; Mohamad Goldust; Georgi Tchernev
Journal:  Open Access Maced J Med Sci       Date:  2018-09-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.